Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<i>WT1</i> and <i>WT1‐AS</i> genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma

30 Aug 2005

Abstract excerpt

BACKGROUND: Ovarian clear cell adenocarcinoma is associated with one of the poorest prognoses among human epithelial ovarian cancers. The authors hypothesized that Wilms tumor suppressor 1 gene (WT1) sense and antisense (WT1-AS) expression and their promoter methylation status could characterize ovarian clear cell adenocarcinoma from ovarian serous adenocarcinoma. METHODS: To test this hypothesis, ovarian cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Renal and related cancers
Share to Reproductive Biology and Fertility

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16134181
DOI: 10.1002/cncr.21397

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<i>WT1</i> and <i>WT1‐AS</i> genes are inactivated by promoter methylation in ovarian clear cell adenocarcinomaPMID 16134181Read ↗

Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinomaSemantic proximity Read ↗

Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinomaSemantic proximity Read ↗

Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinoma.Semantic proximity Read ↗

Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.Semantic proximity Read ↗

ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategiesSemantic proximity Read ↗

Evaluation of SWI/SNF Protein Expression by Immunohistochemistry in Ovarian Clear Cell Carcinoma.Semantic proximity Read ↗

ARID1A mutations in endometriosis-associated ovarian carcinomas.Semantic proximity Read ↗

Epigenetic Inactivation of <b> <i>TMS1/ASC</i> </b> in Ovarian CancerSemantic proximity Read ↗

Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.Semantic proximity Read ↗

Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovarySemantic proximity Read ↗

Wilms' tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathwaysSemantic proximity Read ↗

ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.